CATAPRES Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Catapres, and when can generic versions of Catapres launch?
Catapres is a drug marketed by Boehringer Ingelheim and Lavipharm and is included in two NDAs.
The generic ingredient in CATAPRES is clonidine. There are two drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clonidine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Catapres
A generic version of CATAPRES was approved as clonidine by MYLAN TECHNOLOGIES on July 16th, 2010.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CATAPRES?
- What are the global sales for CATAPRES?
- What is Average Wholesale Price for CATAPRES?
Summary for CATAPRES
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 205 |
| Clinical Trials: | 19 |
| Patent Applications: | 4,501 |
| Drug Prices: | Drug price information for CATAPRES |
| Drug Sales Revenues: | Drug sales revenues for CATAPRES |
| What excipients (inactive ingredients) are in CATAPRES? | CATAPRES excipients list |
| DailyMed Link: | CATAPRES at DailyMed |
Recent Clinical Trials for CATAPRES
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Rigshospitalet, Denmark | Phase 2/Phase 3 |
| Deventer Ziekenhuis | Phase 3 |
| Queen's University, Belfast | Phase 3 |
US Patents and Regulatory Information for CATAPRES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lavipharm | CATAPRES-TTS-1 | clonidine | SYSTEM;TRANSDERMAL | 018891-001 | Oct 10, 1984 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lavipharm | CATAPRES-TTS-3 | clonidine | SYSTEM;TRANSDERMAL | 018891-003 | Oct 10, 1984 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CATAPRES
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-001 | Approved Prior to Jan 1, 1982 | 3,454,701 | ⤷ Start Trial |
| Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-003 | Approved Prior to Jan 1, 1982 | 3,454,701 | ⤷ Start Trial |
| Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-002 | Approved Prior to Jan 1, 1982 | 3,454,701 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CATAPRES
See the table below for patents covering CATAPRES around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 653933 | ⤷ Start Trial | |
| Brazil | 6463142 | ⤷ Start Trial | |
| Switzerland | 409980 | Verfahren zur Herstellung von substituierten 2-Arylamino-1,3-diazacycloalkenen | ⤷ Start Trial |
| Switzerland | 437316 | Verfahren zur Herstellung von substituierten Phenyl-amino-1,3-diazacyclopenten-(2)-Verbindungen | ⤷ Start Trial |
| Switzerland | 451169 | Verfahren zur Herstellung neuer substituierter Phenylamino-1,3-diazacyclopentene-(2) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
DrugChatter Q&A for CATAPRES
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch